References
 
  1. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 1992; 37: 500-503.


  2. Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. J Clin Invest 1972; 51: 2077-84.


  3. Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med 1982; 306: 23-32.


  4. Bell GM, Sawers JSA, Forfar JC, Doig A, Toft AD. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol 1983; 18: 511-16.


  5. Gow SM, Caldwell G, Toft AD, et al. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1987; 64: 364-70.


  6. Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167-70.


  7. Nyström E, Lundberg P-A, Petersen K, Bengtsson C, Lindstedt G. Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic L-thyroxine treatment. Clin Endocrinol 1989; 31: 143-50.


  8. Gow SM, Caldwell G, Toft AD, Beckett GJ. Different hepatic responses to thyroxine replacement in spontaneous and 131I-induced primary hypothyroidism. Clin Endocrinol 1989; 30: 505-12.


  9. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 1990; 263: 1529-32.


  10. Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 1988; 28: 325-33.


  11. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthy-roidism. Br Med J 1996; 313: 539-44.


  12. Ferretti E, Persani L, Jaffrain-Rea M-L, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84: 924-9.


  13. Mudde AH, Reijnders FJL, Nieuwenhuijzen Kruseman AC. Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol 1992; 37: 35-9.


  14. Földes J, Tarjan G, Szathmari M, Varga F, Krosznai I, Horvath CS. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk for osteoporosis? Clin Endocrinol 1993; 39: 521-7.


  15. Mudde AH, Houben AJHM, Nieuwenhuijzen Kruseman AC. Bone metabolism during antithyroid treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994; 41: 421-4.


  16. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in post-menopausal women. Clin Endocrinol 1998; 48: 285-90.


  17. Forfar JC, Feek CM, Miller HC, Toft AD. Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: response to specific antithyroid therapy. Int J Cardiol 1981; 1: 43-8.


  18. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85: 4701-5.


  19. Bearcroft CP, Toms GC, Williams SJ, Noonan K, Monson JP. Thyroxine replacement in postradioiodine hypothyroidism. Clin Endocrinol 1991; 34: 115-8.


  20. Pearce CJ, Himsworth RL. Total and free thyroid hormone concentrations in patients receiving maintenance replacement treatment with thyroxine. Br Med J 1984; 288: 693-5.


  21. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278-89.


  22. Solomon BL, Wartofsky L, Burman, KD. Prevalence of fractures in post-menopausal women with thyroid disease. Thyroid 1993; 3: 17-23.


  23. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.


  24. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 1994; 331: 1249-52.


  25. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344: 1743-9.


  26. MacGregor AG. Why does anybody use thyroid BP? Lancet 1961; 1: 329-32.


  27. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995; 96: 2828-38.


  28. Escobar-Morreale HF, Escobar del Rey F, Obregon MJ, Morreale de Escobar G. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 1996; 137: 2490-502.


  29. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424-9.


  30. Tigas S, Idiculla J, Beckett G, Toft A. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy? Thyroid 2000; 10: 1107-11.


  31. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Am Intern Med 1984; 101: 18-24.


  32. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol 1995; 43: 55-68.


  33. Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85: 2993-3001.


  34. Bastenie PA, Vanhaelst L, Neve P. Coronary artery disease in hypothyroidism, observations in preclinical myxoedema. Lancet 1967; ii: 1221-2.


  35. Hak AE, Pols HAP, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 2000; 132: 270-8.


  36. Cooper DS. Subclinical hypothyroidism. N Engl J Med 2001 (in press).


  37. Hegedüs L, Hansen JM, Feldt-Rasmussen U, Hansen BM, Hoier-Madsen M. Influence of thyroxine treatment on thyroid size and antithyroid peroxidase antibodies in Hashimoto’s thyroiditis. Clin Endocrinol 1991; 35: 235-8.


  38. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-53.


  39. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-4.


  40. DeGroot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 1999; 84: 151-64.


  41. Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998; 81: 443-7.


  42. Aronson R, Offman H, Joffe R, Naylor C. Triiodothyronine augmentation in the treatment of refractory depression: a metaanalysis. Arch Gen Psychiatry 1996; 53: 842-8.


  43. Pollock MA, Sturrock A, Marshall K, et al. Efficacy of thyroxine replacement in patients who feel clinically hypothyroid but are biochemically euthyroid. J Endocrinol 2000; 164 (supplement): abstract 329.